We are live on ! Find out more
BBOT

BridgeBio Oncology
BBOT

53 hedge funds and large institutions have $756M invested in BridgeBio Oncology in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

26% more funds holding

Funds holding: 42 → 53 (+11)

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

15% more capital invested

Capital invested by funds: $658M → $756M (+$98.6M)

1.16% more ownership

Funds ownership: 71.74% → 72.9% (+1.2%)

0% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 12

Holders
53
Holders Change
+11
Holders Change %
+26.19%
% of All Funds
0.64%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.06%
New
15
Increased
12
Reduced
12
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$7.12M
2
LCM
Laurion Capital Management
New York
+$5.08M
3
CCM
Catalio Capital Management
New York
+$4.98M
4
PBA
Paradigm Biocapital Advisors
New York
+$4.79M
5
HS
HighVista Strategies
Massachusetts
+$2.78M

Top Sellers

Rank Fund Capital Flow
1
SCM
Silverarc Capital Management
Massachusetts
-$5.3M
2
ACM
ADAR1 Capital Management
Texas
-$3.33M
3
Millennium Management
Millennium Management
New York
-$1.55M
4
SC
Stempoint Capital
New York
-$1.21M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
$224M – – –
DM
2
Deerfield Management
New York
$61.2M – – –
OFM
3
Omega Fund Management
Massachusetts
$41.2M – – –
Wellington Management Group
4
Wellington Management Group
Massachusetts
$36.4M -$657K -54,260 -2%
AI
5
Alphabet Inc
California
$35.3M – – –
EC
6
EcoR1 Capital
California
$35.3M – – –
ES
7
Enavate Sciences
California
$32.9M – – –
Citadel Advisors
8
Citadel Advisors
Florida
$31.7M -$94.7K -7,817 -0.3%
CCM
9
Catalio Capital Management
New York
$31.4M +$4.98M +410,700 New
PBA
10
Paradigm Biocapital Advisors
New York
$28.3M +$4.79M +395,608 +21%
BlackRock
11
BlackRock
New York
$26.1M +$440K +36,285 +2%
NHAS
12
Novo Holdings A/S
Denmark
$24.6M – – –
LCM
13
Laurion Capital Management
New York
$18.3M +$5.08M +419,138 +40%
Adage Capital Partners
14
Adage Capital Partners
Massachusetts
$17.5M -$1.06M -87,621 -6%
EAM
15
Eventide Asset Management
Massachusetts
$13.4M – – –
OCA
16
Octagon Capital Advisors
New York
$13.1M – – –
AC
17
Armistice Capital
New York
$12.5M +$7.12M +588,000 +143%
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$10.1M -$992K -81,908 -9%
Vanguard Group
19
Vanguard Group
Pennsylvania
$9.9M +$1.74M +143,496 +22%
ACM
20
Aisling Capital Management
New York
$7.07M – – –
Geode Capital Management
21
Geode Capital Management
Massachusetts
$7.04M +$247K +20,385 +4%
CC
22
Casdin Capital
New York
$3.53M – – –
Charles Schwab
23
Charles Schwab
California
$3.49M -$3.68K -304 -0.1%
Millennium Management
24
Millennium Management
New York
$3.02M -$1.55M -128,148 -35%
Fidelity Investments
25
Fidelity Investments
Massachusetts
$3.01M +$948K +78,223 +48%
1
2 3

BBOT Hedge Fund Activity: Q4 2025 in Review

53 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Oncology (BBOT) for Q4 2025, worth a combined $756M — up 15% from $658M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new BBOT positions and 4 closed out — a net gain of 11 holders — while 12 added to existing stakes and 12 trimmed.

The largest buyer was Armistice Capital, adding an estimated $7.12M. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $5.3M sold.

  • 53 institutional investors held BridgeBio Oncology (BBOT) as of Q4 2025, up from 42 in Q3 2025.
  • Funds reported $756M of BridgeBio Oncology stock for Q4 2025, up 15% quarter-over-quarter.
  • 15 funds opened new BridgeBio Oncology positions in Q4 2025 and 4 closed out, a net change of +11 holders.
  • The largest BridgeBio Oncology buyer in Q4 2025 was Armistice Capital, an estimated $7.12M added.
  • The largest BridgeBio Oncology seller in Q4 2025 was Silverarc Capital Management, an estimated $5.3M sold.

Based on aggregated 13F filings for Q4 2025.